Granted Patent
B2
US 12,478,659 · App. 18/154,742 · Granted Nov 25, 2025
Methods of using ZSCAN4 for rejuvenating human cells
Assignee:
Elixirgen Therapeutics, Inc.
A61K38/1709A61K9/51A61K31/7088A61K35/28A61K35/33A61K35/545A61K48/005C12N5/0606C12N5/0609C12N5/0696C12N15/113C12N15/85C12Q1/6806C12Q1/6883C12Q1/6886A61K48/00C12N2310/14C12N2310/531C12N2320/31C12N2501/998C12N2510/04C12N2760/18841C12Q2600/136C12Q2600/156C12Q2600/158
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present disclosure relates to methods for increasing telomere length in one or more human cells and/or increasing genome stability of one or more human cells, for example by contacting one or more human cells with an agent that increases expression of Zscan4 in the one or more human cells. Methods of treating a subject in need of telomere lengthening, treating a disease or condition associated with a genomic and/or chromosome abnormality, of rejuvenating one or more human cells, of rejuvenating tissues or organs, and of rejuvenating a subject in need thereof, for example by contacting one or more human cells in the subject with an agent that increases expression of Zscan4, or by administering to a subject in need thereof, an agent that increases expression of Zscan4 are also provided.
Claims (8)
1 . A method of increasing telomere length in one or more human bone marrow cells or blood cells isolated from a human subject, comprising introducing in vitro into the one or more human bone marrow cells or blood cells an isolated nucleic acid molecule encoding human Zscan4 in the absence of reprogramming factors, wherein introduction of the isolated nucleic acid molecule encoding human Zscan4 induces telomere lengthening in the one or more human bone marrow cells or blood cells as compared to human bone marrow cells or blood cells that are not contacted with the isolated nucleic acid, and wherein the isolated nucleic acid molecule is comprised in a synthetic mRNA or a Sendai virus vector.
2 . The method of claim 1 , wherein the introduction of the isolated nucleic acid molecule encoding human Zscan4 transiently increases Zscan4 activity.
3 . The method of claim 1 , wherein the human bone marrow cells or blood cells comprise hematopoietic stem cells.
4 . The method of claim 1 , wherein the human bone marrow cells or blood cells comprise hematopoietic stem cells and mesenchymal stem cells.
5 . The method of claim 1 , wherein the isolated nucleic acid molecule is comprised in a synthetic mRNA.
6 . The method of claim 5 , wherein the synthetic RNA is produced from a DNA template encoding the human Zscan4 protein by in vitro transcription in the presence of at least one modified nucleotide triphosphate (NTP).
7 . The method of claim 1 , wherein the isolated nucleic acid molecule is comprised a Sendai virus vector.
8 . The method of claim 7 , wherein the Sendai virus vector is a temperature-sensitive Sendai virus vector.
Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 23, 2023
From: KO, MINORU S.H.
To: ELIXIRGEN THERAPEUTICS, INC.
Reel/Frame 064043/0656 →
Continuity (5)
Division
14776707
Provisional Application
61800668
· Mar 15, 2013
References Cited (107)
US 5834193A
· Kozlowski et al.
· 1998
[cited by applicant]
US 5888762A
· Joliot et al.
· 1999
[cited by applicant]
US 6110902A
· Mohler et al.
· 2000
[cited by applicant]
US 6821948B1
· Braun et al.
· 2004
[cited by applicant]
US 8741649B2
· Ko et al.
· 2014
[cited by applicant]
US 9012223B2
· Ko et al.
· 2015
[cited by applicant]
US 9932560B2
· Ko
· 2018
[cited by examiner]
US 20030125242A1
· Rosenecker et al.
· 2003
[cited by applicant]
US 20040005296A1
· Yonemitsu et al.
· 2004
[cited by applicant]
US 20050287648A1
· Smith et al.
· 2005
[cited by applicant]
US 20060024331A1
· Fernandez-Salas et al.
· 2006
[cited by applicant]
US 20060099677A1
· Lee et al.
· 2006
[cited by applicant]
US 20070010476A1
· West et al.
· 2007
[cited by applicant]
US 20100105043A1
· Ko et al.
· 2010
[cited by applicant]
US 20110028880A1
· Uchida et al.
· 2011
[cited by applicant]
US 20110104698A1
· Rudolph
· 2011
[cited by applicant]
US 20190282660A1
· Ko
· 2019
[cited by applicant]
CN 1917902A
· 2007
[cited by applicant]
JP 2013503638A
· 2013
[cited by applicant]
WO WO2001018236A1
· 2001
[cited by applicant]
WO WO2008118957A2
· 2008
[cited by applicant]
WO WO2011028880A2
· 2011
[cited by applicant]
WO WO2012103235A1
· 2012
[cited by applicant]
WO WO2012129342A1
· 2012
[cited by applicant]
WO WO2012158561A1
· 2012
[cited by applicant]
WO WO2012158564A1
· 2012
[cited by applicant]
WO WO2014144932A2
· 2014
[cited by applicant]
Aebischer et al., (1994). “Transplantation in Humans of Encapsulated Xenogeneic Cells Without Immunosuppression: A Preliminary Report,” Transplantation, 58(11):1275-1277.
[cited by applicant]
Agarwal et al., (2010). “Telomere Elongation in Induced Pluripotent Stem Cells from Dyskeratosis Congenita Patients,” Nature, 464:292-296.
[cited by applicant]
Alter, (2017). “Inherited Bone Marrow Failure Syndromes: Considerations Pre- and Posttransplant,” Blood, 130(21):2257-2264.
[cited by applicant]
Amano et al., (2015). “Correction of Down syndrome and Edwards syndrome aneuploidies in human cell cultures,” DNA Res, 22(5):331-342.
[cited by applicant]
Armanios et al., (2012). “The Telomere Syndromes,” Nature Reviews Genetics, 13(10):693-704.
[cited by applicant]
Avdeeva et al., (2010). “Requirements for production and control of medicines based on monoclonal antibodies used for treatment,” Biopreparations, pp. 11-14. English abstract.
[cited by applicant]
Avdeeva et al., (2015). “The safety of medicines of monoclonal antibodies connected with manifestation of their immunogenicity,” Immunology, 4:247-256. English abstract.
[cited by applicant]
Bogliolo et al., (2002). “The Fanconi Anaemia Genome Stability and Tumour Suppressor Network,” Mutagenesis, 17(6):529-538.
[cited by applicant]
Brambrink et al., (2008). “Sequential Expression of Pluripotency Markers during Direct Reprogramming of Mouse Somatic Cells,” Cell Stem Cell, 2:151-159.
[cited by applicant]
Brunt et al., (2012). “Stem Cells and Regenerative Medicine—Future Perspectives,” Can. J. Physiol. Pharmacol., 90:327•335.
[cited by applicant]
Carter et al., (2008). “An in situ hybridization-based screen for heterogeneously expressed genes in mouse ES cells,” Gene Expr Patterns, 8(3):181-198.
[cited by applicant]
Cetin et al., (2010). “How to Survive Aneuploidy,” Cell, 143(1):27-29.
[cited by applicant]
Chen et al., (2013). “Fusion protein linkers: property, design and functionality,” Advanced Drug Delivery Reviews, 65(10):1357-1369, 32 pages.
[cited by applicant]
Dietz et al., (2011) “Disease-specific hematopoietic cell transplantation: nonmyeloablative conditioning regimen for dyskeratosis congenita”, Bone Marrow Transplantation, 46:98-104.
[cited by applicant]
Elliott et al., (1997). “Intercellular Trafficking and Protein Delivery by a Herpesvirus Structural Protein,” Cell, 88(2):223-233.
[cited by applicant]
European Search Report and Written Opinion received for European Patent Application No. 20186939.3 mailed on Jan. 22, 2021, 9 pages.
[cited by applicant]
Extended European Search Report received for European Patent Application No. 14762788.9, mailed on Jun. 30, 2016, 11 pages.
[cited by applicant]
Falco et al., (2007). “Zscan4: A Novel Gene Expressed Exclusively in Late 2-Cell Embryos and Embryonic Stem Cells,” Developmental Biology, 307:539-550.
[cited by applicant]
Fleisig et al., (2007). “Telomerase as a Clinical Target: Current Strategies and Potential Applications,” Experimental Gerontology, 42:102-112.
[cited by applicant]
Fusaki et al., (2009). “Efficient Induction of Transgene-Free Human Pluripotent Stem Cells using a Vector Based on Sendai Virus, An RNA Virus that does not Integrate into the Host Genome,” Proceedings of the Japan Acade…
[cited by applicant]
Gadalla et al., (2010). “Telomere Length in Blood, Buccal Cells, and Fibroblasts from Patients with Inherited Bone Marrow Failure Syndromes,” Aging, 2(11):867-874.
[cited by applicant]
Gadalla et al., (2011). “Telomere biology in hematopoiesis and stem cell transplantation,” Blood Rev, 25:261-269.
[cited by applicant]
Güngör et al., (2003). “Nonmyeloablative Allogeneic Hematopoietic Stem Cell Transplantation for Treatment of Dyskeratosis Congenita,” Bone Marrow Transplant, 31:407-410.
[cited by applicant]
Hamatani et al., (2004). “Dynamics of Global Gene Expression Changes during Mouse Preimplantation Development,” Developmental Cel, 6:117-131.
[cited by applicant]
Harley et al., (2011). “A Natural Product Telomerase Activator As Part of a Health Maintenance Program,” Rejuvenation Res., 14(1):45-56.
[cited by applicant]
Hawiger (1999). “Noninvasive intracellular delivery of functional peptides and proteins,” Current Opinion in Chemical Biology, 3(1):89-94.
[cited by applicant]
Heitz et al., (2009). “Twenty years of cell-penetrating peptides: from molecular mechanisms to therapeutics,” British Journal of Pharmacology, 157(2):195-206.
[cited by applicant]
Hermann et al., (2004). “Efficient Generation of Neural Stem Cell-Like Cells from Adult Human Bone Marrow Stromal Cells,” Journal of Cell Science, 117(19):4411-4422.
[cited by applicant]
Hirata et al., (2012). “Zscan4 Transiently Reactivates Early Embryonic Genes During the Generation of Induced Pluripotent Stem Cells,” Science Reports, 2(208):1-11.
[cited by applicant]
International Preliminary Report on Patentability received for PCT Application No. PCT/US2014/029537, mailed on Sep. 24, 2015, 16 pages.
[cited by applicant]
International Search Report and Written Opinion received for PCT Patent Application No. PCT/US2014/029537 mailed on Oct. 17, 2014, 21 pages.
[cited by applicant]
James et al., (1971). “Radiological Features of the Most Common Autosomal Disorders: Trisomy 21-22 (Mongolism or Down's Syndrome), Trisomy 18, Trisomy 13-15, And The Cri Du Chat Syndrome,” Clinical Radiology, 22:417-433.
[cited by applicant]
Jiang et al., (2013). “Zscan4 promotes genomic stability during reprogramming and dramatically improves the quality of iPS cells as demonstrated by tetraploid complementation,” Cell Research, 23:92-106.
[cited by applicant]
Kaji et al., (2009). “Virus free induction of pluripotency and subsequent excision of reprogramming factors,” Nature, 458(7239):771-775.
[cited by applicant]
Kay et al., (2011). “State-of-the-art gene-based therapies: the road ahead,” Nature Reviews Genetics, 12(5):316-328.
[cited by applicant]
Kean et al., (2013). “MSCs: Delivery Routes and Engraftment, Cell-Targeting Strategies, and Immune Modulation,” Stem Cells International, 2013(732742 2013), 13 pages.
[cited by applicant]
Kim et al., (2009). “Generation of Human Induced Pluripotent Stem Cells by Direct Delivery of Reprogramming Proteins Cell,” Stem Cell, 4(6):472-476.
[cited by applicant]
Ko et al., (2000). “Large scale cDNA analysis reveals phased gene expression patterns during preimplantation mouse development,” Development, 127:1737-1749.
[cited by applicant]
Laus et al., (2000). “Enhanced major histocompatibility complex class I-dependent presentation of antigens modified with cationic and fusogenic peptides,” Nature Biotechnology, 18:1269-1272.
[cited by applicant]
Leteurtre et al., (1999). “Accelerated telomere shortening and telomerase activation in Fanconi's anaemia,” British Journal of Haemotology, 105:883-893.
[cited by applicant]
Liu et al., (2014). “Cell-penetrating peptide-mediated delivery of TALEN proteins via bioconjugation for genome engineering,” PLoS one, 9(1):e85755, 7 pages.
[cited by applicant]
Marrone et al., (2007) “Telomerase reverse-transcriptase homozygous mutations in autosomal recessive dyskeratosis congenita and Hoyeraal-Hreidarsson syndrome”, Blood, 110(13):4198-205.
[cited by applicant]
Mi et al., (2000). “Characterization of a Class of Cationic Peptides Able to Facilitate Efficient Protein Transduction in Vitro and in Vivo,” Molecular Therapy, 2(4):339-347.
[cited by applicant]
Misra (2013). “Human Gene Therapy: A Brief Overview of The Genetic Revolution,” J Assoc Physicians India, 61:127-133.
[cited by applicant]
Moore et al., (2013). “DNA Methylation and Its Basic Function,” Neuropsychopharmacology Reviews, 38: 23-38.
[cited by applicant]
Moskalev, (2009). “Prospective Trends in Genetics of Aging And Longevity,” Uspekhi gerontologii, 22(1):92-103. English abstract.
[cited by applicant]
Nakanishi et al., (2012). “Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine,” Current Gene Therapy, 12(5):410-416.
[cited by applicant]
Naldini (2011). “Ex Vivo Gene Transfer and Correction for Cell-Based Therapies,” Nature Reviews: Genetics, 12:301-315.
[cited by applicant]
Nguyen et al., (2010). “Methods to Assess Stem Cell Lineage, Fate and Function,” Advanced Drug Delivery Reviews, 62:1175-1186.
[cited by applicant]
Okita et al., (2008). “Generation of Mouse Induced Pluripotent Stem Cells Without Viral Vectors,” Science, 322(5903):949-953.
[cited by applicant]
Peng et al., (2006). “Visualizing common deletion of mitochondrial DNA-augmented mitochondrial reactive oxygen species generation and apoptosis upon oxidative stress,” Biochimica et Biophysica Acta, 1762:241-55.
[cited by applicant]
Rondal, (2020). “Down syndrome: A curative prospect?,” AIMS Neuroscience, 7(2):168-93.
[cited by applicant]
Sharov et al., (2003). “Transcriptome Analysis of Mouse Stem Cells and Early Embryos,” PLoS Biology, 1(3):410-419.
[cited by applicant]
Stadtfeld et al., (2008). “Induced pluripotent stem cells generated without viral integration,” Science, 322(5903):945-949.
[cited by applicant]
Takahashi et al. (2007). “Induction of pluripotent stem cells from adult human fibroblasts by defined factors,” Cell, 131:861-872.
[cited by applicant]
University of Chicago Medical Center, (2015). “Long telomere length associated with increased lung cancer risk,” Available online at <https://medicalxpress.com/news/2015-07-telomere-length-lung-cancer.html>, 3 pages.
[cited by applicant]
Wang et al., (2008). “Chromosomal transposition of PiggyBac in mouse embryonic stem cells,” Proc Natl Acad Sci USA, 105(27):9290-9295.
[cited by applicant]
Wernig et al., (2008). “A drug-inducible transgenic system for direct reprogramming of multiple somatic cell types,” Nat Biotechnol, 26(8):916-924.
[cited by applicant]
Westin et al., (2007). “Telomere Restoration and Extension of Proliferative Lifespan in Dyskeratosis Congenita Fibroblasts,” Aging Cell, 6:383-394.
[cited by applicant]
Widmer et al., (2010). “Hemoglobin Can Attenuate Hydrogen Peroxide-Induced Oxidative Stress by Acting as An Antioxidative Peroxidase,” Antioxidants & Redox Signaling, 12(2):185-198.
[cited by applicant]
Yegorov (2010). “Telomeres, Telomerase, Oncogenesis and Measure of Health Clinical Oncohematology,” Fundamental Studies and Clinical Practice, 3(2):184-197 (Foreign Copy Only).
[cited by applicant]
Yu et al., (2009). “Human Induced Pluripotent Stem Cells Free of Vector and Transgene Sequences,” Science, 324(5928):797-801.
[cited by applicant]
Yusa et al., (2009). “Generation of transgene-free induced pluripotent mouse stem cells by the piggyBac transposon,” Nat Methods, 6(5):363-369.
[cited by applicant]
Zalzman et al., (2010). “Zscan4 Regulates Telomere Elongation and Genomic Stability in ES Cells,” Nature, 464(7290):858-863.
[cited by applicant]
Zhao et al., (2004). “Intracellular cargo delivery using tat peptide and derivatives,” Medicinal Research Reviews, 24(1):1-12.
[cited by applicant]
Zhou et al., (2009). “Generation of Induced Pluripotent Stem cells Using Recombinant Proteins Cell,” Stem Cell, 4(5):381-384.
[cited by applicant]
Partial European Search Report and Written Opinion received for European Patent Application No. 24167285.6 mailed on Oct. 10, 2024, 15 pages.
[cited by applicant]
Extended European Search Report and Written Opinion received for European Patent Application No. 24167285.6 mailed on Jan. 13, 2025, 14 pages.
[cited by applicant]